Symposium on Risks and Opportunities of AI in Clinical Drug Development - Institute for Experiential AI

Symposium on Risks and Opportunities of AI in Clinical Drug Development

 

Register today to attend virtually or in-person.

The Symposium on Risks and Opportunities of AI in Clinical Drug Development is an event jointly sponsored by Pfizer Inc., Northeastern University, the American Statistical Association (ASA), the Statistics Department and Data Science Institute at Columbia University, and OHDSI.

This event is designed to serve as a platform for distinguished statisticians, data scientists, regulators, and other professionals to address the challenges and opportunities of AI in pharmaceutical medicine; to foster collaboration among industry, academia, regulatory agencies, and professional associations; and to propose recommendations with policy implications for proper implementation of AI in promoting public health.

As a convener of researchers in the fields of AI, data science, biotechnology, computational medicine, and more, industry partners, academic faculty, and entrepreneurs, the Roux Institute at Northeastern University is uniquely positioned to host this event and connect the experts needed to tackle the challenges and opportunities presented.

The Roux Institute at Northeastern University is a center of activity for both the Observational Health Data Sciences and Informatics Center (OHDSI), which advances healthcare by fostering reproducible research through open science, and the Institute for Experiential Artificial Intelligence (EAI), which researches and develops human-centric AI solutions that leverage machine technology to extend human intelligence. ​

Co-sponsored by Pfizer, the American Statistical Association, Northeastern University, and Columbia University, the Roux Institute at Northeastern University is pleased to host this symposium focused on Risks and Opportunities in Clinical Drug Development.

Biography